BioArctic is a Swedish biopharma company focused on therapies for neurodegenerative diseases, especially Alzheimer’s disease. It co-developed the antibody lecanemab (Leqembi) with Eisai, based on research into disease-modifying approaches to amyloid pathology. The company partners on late-stage development and commercialisation while advancing its own pipeline in brain disorders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,289.6 | — | 1,021.5 | — |
| Q2 2025 | 392.1 | — | 96.5 | — |
| Q3 2025 | 133.3 | — | -86.9 | — |
| Q4 2025 | 184 | — | -8.8 | — |
| Q1 2026 | 437.6 | -66.1% | 212.4 | -79.2% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Munters Group AB (publ) (MTRS), Clas Ohlson AB (publ) (CLAS B), Bravida Holding AB (publ) (BRAV), Peab AB (publ) (PEAB B), Asker Healthcare Group AB (publ) (ASKER), Röko AB (publ) (ROKO B)